Butyl stearate prolongs the drug release period of isoperidone‑loaded poly (lactic‑co‑glycolic acid) microspheres: In vitro and in vivo investigation

Sun,Fengying; Yu,Changhui; Liu,Ximing; Wang,Dan; Liu,Na; Liu,Jiaxin; Teng,Lesheng; Li,Youxin

doi:10.3892/mmr.2018.9797

Butyl stearate prolongs the drug release period of isoperidone‑loaded poly (lactic‑co‑glycolic acid) microspheres: In vitro and in vivo investigation

Authors:
- Fengying Sun
- Changhui Yu
- Ximing Liu
- Dan Wang
- Na Liu
- Jiaxin Liu
- Lesheng Teng
- Youxin Li
View Affiliations

Affiliations: The Center for Pharmaceutical Research, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China
Published online on: December 24, 2018 https://doi.org/10.3892/mmr.2018.9797
Pages: 1595-1602
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of butyl stearate on t‑butoxyl paliperidone derivative (isoperidone)‑loaded poly(lactide‑co‑glycolide) (PLGA) microspheres. The mechanism of drug release rate delay by butyl stearate was examined by accelerated testing, morphological observation, thermal and fluorescence analyses. In vivo pharmacokinetic study was conducted on female beagle dogs. Spherical microspheres with smooth surfaces, small internal pores and shell structures were initially prepared. It was found that 3% (w/w) butyl stearate prolonged the in vitro drug release period from 46 to 82 days, and in vivo release period from 20 to 27 days. Furthermore, the results demonstrated that the green fluorescence imaging of isoperidone approaching the cores of microspheres with 3% butyl stearate was brighter than in microspheres without additives. In conclusion, it was shown that butyl stearate affected the microsphere structure, isoperidone microsphere distribution and isoperidone crystallinity. The results of the present study thus provide a potential method to develop sustained‑release preparations.

View Figures

View References

1	Wischke C and Schwendeman SP: Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm. 364:298–327. 2008. View Article : Google Scholar : PubMed/NCBI
2	Wang LY, Cai MM, Liu Y, Yang T, Zeng Y, Zhang Y, Li Q, Zhu B and Ma G: Polymer hydrophobicity regulates paclitaxel distribution in microspheres, release profile and cytotoxicity in vitro. Powder Technology. 275:77–84. 2015. View Article : Google Scholar
3	Zhao J, Wang L, Fan C, Yu K, Liu X, Zhao X, Wang D, Liu W, Su Z, Sun F and Li Y: Development of near zero-order release PLGA-based microspheres of a novel antipsychotic. Int J Pharm. 516:32–38. 2017. View Article : Google Scholar : PubMed/NCBI
4	Amann LC, Gandal MJ, Lin R, Liang Y and Siegel SJ: In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Pharm Res. 27:1730–1737. 2010. View Article : Google Scholar : PubMed/NCBI
5	D'Souza S, Faraj J and DeLuca P: Microsphere delivery of Risperidone as an alternative to combination therapy. Eur J Pharm Biopharm. 85:631–639. 2013. View Article : Google Scholar : PubMed/NCBI
6	Okada H: One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 28:43–70. 1997. View Article : Google Scholar : PubMed/NCBI
7	Sharifi R, Knoll LD, Smith J and Kramolowsky E: Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology. 51:271–276. 1998. View Article : Google Scholar : PubMed/NCBI
8	Gupta SL, Rao KP, Choudary K and Pratima S: Preformulation studies of biodegradable drug implants of meloxicam for orthopedic patient care. J Pharm Sci Technol. 3:494–498. 2011.
9	Takada S, Kurokawda T, Miyazaki K, Iwasa S and Ogawa Y: Utilization of an amorphous form of a water-soluble GPIIb/IIIa antagonist for controlled release from biodegradable microspheres. Pharm Res. 14:1146–1150. 1997. View Article : Google Scholar : PubMed/NCBI
10	Makino K, Mogi T, Ohtake N, Yoshida M, Ando S, Nakajima T and Ohshima H: Pulsatile drug release from poly(lactide-co-glycolide) microspheres: How does the composition of the polymer matrices affect the time interval between the initial burst and the pulsatile release of drugs? Colloids Surf B Biointerfaces. 19:173–179. 2000. View Article : Google Scholar
11	Ghalanbor Z, Körber M and Bodmeier R: Improved lysozyme stability and release properties of poly(lactide-co-glycolide) implants prepared by hot-melt extrusion. Pharm Res. 27:371–379. 2010. View Article : Google Scholar : PubMed/NCBI
12	Sun F, Sui C, Teng L, Liu X, Teng L, Meng Q and Li Y: Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres. Int J Pharm. 397:44–49. 2010. View Article : Google Scholar : PubMed/NCBI
13	Kazuhiko J, Masahiro N and Miho K: Controlled release of aclarubicim, an anticancer antibiotic, from poly-β-hydroxybutyric acid microspheres. J Controlled Release. 4:25–32. 1986. View Article : Google Scholar
14	Munarin F, Giuliano L, Bozzini S, Tanzi MC and Petrini P: Mineral phase deposition on pectin microspheres. Mat Sci Eng C. 30:491–496. 2010. View Article : Google Scholar
15	Ni L, Jie X, Wang P, Li S, Hu S, Li Y, Li Y and Acharya K: Characterization of unsaturated fatty acid sustained-release microspheres for long-term algal inhibition. Chemosphere. 120:383–390. 2015. View Article : Google Scholar : PubMed/NCBI
16	Angadi SC, Manjeshwar LS and Aminabhavi TM: Stearic acid-coated chitosan-based interpenetrating polymer network microspheres: Controlled release characteristics. Ind Eng Chem Res. 50:4504–4514. 2011. View Article : Google Scholar
17	Urata T, Arimori K and Nakano M: Modification of release rates of cyclosporin A from polyl(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. J Control Release. 58:133–141. 1999. View Article : Google Scholar : PubMed/NCBI
18	Chwieduk CM and Keating GM: Paliperidone extended release: A review of its use in the management of schizophrenia. Drugs. 70:1295–1317. 2010. View Article : Google Scholar : PubMed/NCBI
19	Sun F, Su Z, Sui C, Zhang C, Yuan L, Meng Q, Teng L and Li Y: Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives-comparison to paliperidone and risperidone in mice and rats. Basic Clin Pharmacol Toxicol. 107:656–662. 2010. View Article : Google Scholar : PubMed/NCBI
20	Sarı A, Biçer A and Karaipekli A: Synthesis, characterization, thermal properties of a series of stearic acid esters as novel solid-liquid phase change materials. Mat Lett. 63:1213–1216. 2009. View Article : Google Scholar
21	Huang W, Shi YN, Wang CH, Yu KT, Sun FY and Li YX: Using spray-dried lactose monohydrate in wet granulation method for a low-dose oral formulation of a paliperidone derivative. Powder Technol. 246:379–394. 2013. View Article : Google Scholar
22	Lu S, Xing J, Zhang Z and Jia G: Preparation and characterization of polyurea/polyurethane double-shell microcapsules containing butyl stearate through interfacial polymerization. J Appl Poly Sci. 121:3377–3383. 2011. View Article : Google Scholar
23	Sakamoto S, Komatsu T, Ueno T, Hanaoka K and Urano Y: Fluorescence detection of serum albumin with a turnover-based sensor utilizing Kemp elimination reaction. Bioorg Med Chem Lett. 27:3464–3467. 2017. View Article : Google Scholar : PubMed/NCBI
24	Vrancken MN and Claeys DA: Process for encapsulating water and compounds in aqueous phase by evaporation. US Patent 3,523,906. Filed April 25, 1968; issued. August 11–1970.
25	Wang J and Schwendeman SP: Mechanisms of solvent evaporation encapsulation processes: Prediction of solvent evaporation rate. J Pharm Sci. 88:1090–1099. 1999.PubMed/NCBI
26	Birnbaum DT, Kosmala JD, Henthorn DB and Brannon-Peppas L: Controlled release of beta-estradiol from PLAGA microparticles: The effect of organic phase solvent on encapsulation and release. J Control Release. 65:375–387. 2000. View Article : Google Scholar : PubMed/NCBI
27	Soppimath KS and Aminabhavi TM: Ethyl acetate as a dispersing solvent in the production of poly(DL-lactide-co-glycolide) microspheres: Effect of process parameters and polymer type. J Microencapsul. 19:281–292. 2002. View Article : Google Scholar : PubMed/NCBI
28	Birnbaum DT and Brannon-Peppas L: Microparticle drug delivery systems. Drug Delivery Systems in Cancer Therapy (Springer). 117–135. 2004.
29	Mogi T, Ohtake N, Yoshida M, Chimura R, Kamaga Y, Ando S, Tsukamoto T, Nakajima T, Uenodan H, Otsuka M, et al: Sustained release of 17β-estradiol from poly(lactide-co-glycolide) microspheres in vitro and in vivo. Colloids Surface B Biointerfaces. 17:153–165. 2000. View Article : Google Scholar
30	Mao SR, Shi Y, Li L, Xu J, Schaper A and Kissel T: Effects of process and formulation parameters on characteristics and internal morphology of poly(D,L-lactide-co-glycolide) microspheres formed by the solvent evaporation method. Eur J Pharm Biopharm. 68:214–223. 2008. View Article : Google Scholar : PubMed/NCBI